ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Hodgkin Lymphoma in New Haven, CT

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Lymphoma
B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Leukemia
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Cancer

Non-Hodgkin Lymphoma trials near New Haven, CT, USA:

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma (RELATIVITY-069)

and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma...

Enrolling
Hodgkin Disease
Lymphoma, Non-Hodgkin
Drug: Relatlimab
Drug: Nivolumab

Phase 1, Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

New Haven, Connecticut, United States and 73 other locations

The purpose of this study was to evaluate whether copanlisib in combination with rituximab is superior to placebo in combination with rituximab in pr...

Active, not recruiting
Lymphoma,Non-Hodgkin
Drug: Placebo
Drug: Copanlisib (Aliqopa, BAY80-6946)

Phase 3

Bayer
Bayer

Harrison, New York, United States and 186 other locations

Part 1: To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R/R FL.Part 2: To characterize th...

Active, not recruiting
Non Hodgkin Lymphoma
Drug: acalabrutinib
Drug: rituximab (IV)

Phase 1, Phase 2

Acerta Pharma
Acerta Pharma

Hawthorne, New York, United States and 31 other locations

This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/...

Active, not recruiting
Lymphoma, Non-Hodgkin
Drug: Fludarabine
Drug: JCAR017

Phase 2

Celgene
Celgene

New Haven, Connecticut, United States and 55 other locations

JNJ 67856633 when administered together in participants with B cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leu...

Active, not recruiting
Lymphoma, Non-Hodgkin
Chronic Lymphocytic Leukemia
Drug: JNJ-67856633
Drug: JNJ-64264681

Phase 1

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Stony Brook, New York, United States and 27 other locations

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purp-...

Enrolling
Non-Hodgkin Lymphoma
Drug: Pirtobrutinib
Drug: Ibrutinib

Phase 2

Genmab
Genmab

New Haven, Connecticut, United States and 74 other locations

Patients with non-Hodgkin Lymphoma will be treated with CD38-SADA:177Lu-DOTA complex (The IMP is a two-step radioimmunothe...

Enrolling
Non-hodgkin Lymphoma
Drug: CD38-SADA:177Lu-DOTA Complex

Phase 1

Y-mAbs Therapeutics
Y-mAbs Therapeutics

Stony Brook, New York, United States and 5 other locations

ATG-031 study (alias: PERFORM) is a multicenter, open-label, Phase 1 study of ATG-031 in patients with advanced solid tumors or B-NHL. The study desi...

Enrolling
B-cell Non-Hodgkin Lymphomas
Advanced Solid Tumors
Drug: ATG-031

Phase 1

Antengene
Antengene

New Haven, Connecticut, United States and 3 other locations

Targeted drug therapies have greatly improved outcomes for patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) and non...

Active, not recruiting
Follicular Lymphoma
Diffuse Large B Cell Lymphoma
Drug: DTRM-555

Phase 2

Zhejiang DTRM Biopharma

New Haven, Connecticut, United States and 7 other locations

This study is researching an investigational drug, odronextamab, in adult patients B-cell non-Hodgkin's lymphoma (B-NHL).T...

Enrolling
B-cell Non-Hodgkin Lymphoma (B-NHL)
Drug: Odronextamab

Phase 2

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Stony Brook, New York, United States and 137 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems